We are live on ! Find out more
CBMG

Cellular Biomedicine Group, Inc.
CBMG

Delisted

CBMG was delisted on the 19th of February, 2021.

Back to rankings

73 hedge funds and large institutions have $78.5M invested in Cellular Biomedicine Group, Inc. in 2020 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

933% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 3

62% more funds holding

Funds holding: 45 → 73 (+28)

50% more capital invested

Capital invested by funds: $52.2M → $78.5M (+$26.3M)

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

58% less call options, than puts

Call options by funds: $492K | Put options by funds: $1.18M

Holders
73
Holders Change
+28
Holders Change %
+62.22%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
18
Reduced
15
Closed
3
Calls
$492K
Puts
$1.18M
Net Calls
-$687K
Net Calls Change
-$687K

Top Buyers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
+$3.96M
2
GCL
Glazer Capital LLC
New York
+$3.4M
3
Man Group
Man Group
United Kingdom
+$2.36M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$2.32M
5
WIC
Water Island Capital
New York
+$2.24M

Top Sellers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
-$8.92M
2
PIM
Platinum Investment Management
Australia
-$2.04M
3
MAM
Martingale Asset Management
Massachusetts
-$810K
4
Bessemer Group
Bessemer Group
New Jersey
-$732K
5
Russell Investments Group
Russell Investments Group
United Kingdom
-$495K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$628K +$575K +34,224 New
Capstone Investment Advisors
27
Capstone Investment Advisors
New York
$601K +$551K +32,792 New
Ameriprise
28
Ameriprise
Minnesota
$582K +$533K +31,732 New
WAM
29
Wolverine Asset Management
Illinois
$546K +$501K +29,811 New
Charles Schwab
30
Charles Schwab
California
$526K -$18.1K -1,074 -4%
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$479K +$20.2K +1,200 +5%
AGM
32
Alpine Global Management
New York
$459K +$420K +25,000 New
UBS Group
33
UBS Group
Switzerland
$441K +$283K +16,859 +235%
Two Sigma Investments
34
Two Sigma Investments
New York
$440K +$137K +8,148 +51%
GC
35
Guggenheim Capital
Illinois
$402K +$368K +21,895 New
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$389K – – –
PP
37
Paloma Partners
Connecticut
$362K +$332K +19,740 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$346K – – –
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$340K – – –
SG Americas Securities
40
SG Americas Securities
New York
$333K +$192K +11,435 +170%
YCM
41
Yakira Capital Management
Connecticut
$323K +$296K +17,588 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$288K -$36.6K -2,179 -12%
TRCT
43
Tower Research Capital (TRC)
New York
$252K +$183K +10,889 +382%
DTL
44
Dynamic Technology Lab
Singapore
$252K +$231K +13,748 New
OR
45
Olympiad Research
Connecticut
$247K +$227K +13,484 New
Wells Fargo
46
Wells Fargo
California
$239K -$36.6K -2,180 -14%
AllianceBernstein
47
AllianceBernstein
Tennessee
$237K -$40.3K -2,400 -16%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$237K – – –
VIA
49
Vident Investment Advisory
Georgia
$228K +$33.2K +1,975 +19%
AIG
50
American International Group
New York
$135K -$2.81K -167 -2%
1
2
3 4

CBMG Hedge Fund Activity: Q3 2020 in Review

73 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2020, worth a combined $78.5M — up 50% from $52.2M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new CBMG positions and 3 closed out — a net gain of 28 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was Candriam SCA, opening a new position worth an estimated $3.96M. The largest seller was ARK Investment Management, cutting an estimated $8.92M.

  • 73 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2020, up from 45 in Q2 2020.
  • Funds reported $78.5M of Cellular Biomedicine Group, Inc. stock for Q3 2020, up 50% quarter-over-quarter.
  • 31 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2020 and 3 closed out, a net change of +28 holders.
  • The largest Cellular Biomedicine Group, Inc. buyer in Q3 2020 was Candriam SCA, an estimated $3.96M added.
  • The largest Cellular Biomedicine Group, Inc. seller in Q3 2020 was ARK Investment Management, an estimated $8.92M sold.

Based on aggregated 13F filings for Q3 2020.